Reach Us +1-218-451-2974


Caroline Tanner | OMICS International
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Caroline Tanner



Dr. Tanner is the Director of the San Francisco PADRECC. She comes to us from the Clinical Research department of the California Parkinson's Institute and Clinical Center. She is board certified in neurology, completed a residency in neurology and fellowship in clinical neuropharmacology and movement disorders at Rush University, and a doctorate in environmental health sciences at the University of California Berkeley. Dr. Tanner's clinical practice specializes in movement disorders - particularly Parkinson's disease, atypical Parkinsonism, and dystonia. Her research interests include investigations of descriptive epidemiology, environmental and genetic determinants, biomarkers, early detection, non-motor disease features and interventions for the secondary prevention, disease modification and symptomatic treatment of movement disorders, and neurodegenerative diseases. Dr. Tanner received the Movement Disorders Research Award from the American Academy of Neurology in 2012. She has experience on national and international committees specific to movement disorders and in academic research on Parkinson's disease, dystonia, and Huntington's disease.

Research Interest

Parkinsonism, and dystonia ,
Alzheimers Disease,Advances in Alzheimers Therapy,Alzheimers Medicine,Alzheimers Products & Market Analysis,Alzheimers Syntomas,Diagnostic Alzheimer,Pancreatic Enzyme Replacement Therapy,Heavy Chain Diseases